Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia

Muhammad Umair Mushtaq, MD, Sibgha Gull Chaudhary, MD, Laura C. Michaelis, MD, Karen-Sue B. Carlson, MD PhD, Sameem Abedin, MD, Lyndsey Runass, MD, Michael J. Fallon, PharmD, Alexandra M. Harrington, MD, Mark Juckett, MD, Aric C. Hall, MD, Ryan J. Mattison, MD, Ehab L. Atallah, MD, Guru Subramanian Guru Murthy, MBBS

Blood (2018) 132 (Supplement 1): 2708.

https://doi.org/10.1182/blood-2018-99-113764

Published: 2018

Journal Articles

A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies

Christopher R. D'Angelo, MD, Aric C. Hall, MD, Kyungmann Kim, PhD, Ryan J. Mattison, MD, Walter L. Longo, MD, Peiman Hematti, MD, Natalie Scott Callander, MD, Mark Juckett, MD

Blood (2018) 132 (Supplement 1): 2107.

https://doi.org/10.1182/blood-2018-99-112670

Published: 2018

Journal Articles

The Utility Of Monitoring Chimerism: More Predictive For Nonablative Regimens?

Lyndsey Runaas, MD, Walter L. Longo, MD, Mark Juckett, MD, Wayne Borcherding, BS, Peiman Hematti, MD, Rachel J Cook, MD, MS

Blood (2013) 122 (21): 5490.

https://doi.org/10.1182/blood.V122.21.5490.5490

Published: 2013

Journal Articles

Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

Thomas Prebet, M.D., Ph.D., Steven D. Gore, M.D., Zhuoxin Sun, PhD, Peter L. Greenberg, MD, Mark Juckett, MD, Lisa Malick, Mitchell R Smith, MD, PhD, Elisabeth Paietta, PhD, Magdalena Czader, Janice Gabrilove, M.D., Harry P Erba, DM, PhD, Martin S. Tallman, MD

Blood (2010) 116 (21): 601.

https://doi.org/10.1182/blood.V116.21.601.601

Published: 2010

Journal Articles

Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults

Willis H. Navarro, MD, Manza-A Agovi, MPH, Brent Logan, PhD, Andrea Bacigalupo, MD, Karen K Ballen, MD, Brian J. Bolwell, MD, Haydar Frangoul, MD, Vikas Gupta, MD, MRCP, MRCPath, Theresa Hahn, PhD, Mark Juckett, MD, Hillard M. Lazarus, MD, Mark R. Litzow, MD, Jane Liesveld, MD, Jan Moreb, MD, David Marks, MD, PhD, Philip L. McCarthy, MD, J. Douglas Rizzo, MD, MS

Blood (2008) 112 (11): 51.

https://doi.org/10.1182/blood.V112.11.51.51

Published: 2008

Journal Articles

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Martha Raschko, MD, Stephanie Markovina, Shigeki Miyamoto, PhD, Walter Longo, MD, Eliot Williams, MD, Thomas McFarland, MD, Jae Werndli, Elisabeth Wagner, Mark Juckett, MD, Natalie Callander, MD

Blood (2007) 110 (11): 1173.

https://doi.org/10.1182/blood.V110.11.1173.1173

Published: 2007

NARROW

Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia

A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies

The Utility Of Monitoring Chimerism: More Predictive For Nonablative Regimens?

Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia

A Phase II Study of Decitabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Patients with Myeloid Malignancies

The Utility Of Monitoring Chimerism: More Predictive For Nonablative Regimens?

Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only